Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication [Mercorelli B.*, Luganini A.,* co-fisrt author]

(Article begins on next page)

04 May 2024

The publisher's version is available at:
http://linkinghub.elsevier.com/retrieve/pii/S2451945616300034

When citing, please refer to the published version.

Link to this full text:
http://hdl.handle.net/2318/1564431

iris - AperTO

Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication

Authors

Beatrice Mercorelli, Anna Luganini, Giulio Nannetti, Oriana Tabarrini, Giorgio Palu`, Giorgio Gribaudo, Arianna Loregian

Correspondence arianna.loregian@unipd.it

In Brief Mercorelli et al. describe an approach for identifying inhibitors of the viral transcription factor IE2, which plays a major role in HCMV replication, by using a fluorescence-based cellular assay. This yields to small molecules that could be repurposed as anti-HCMV drugs.

Highlights

d A cell-based assay was developed and validated for screening inhibitors of HCMV IE2

d Discovery of new inhibitors of HCMV replication in the low-micromolar range

d Follow-up studies reveal inhibition of viral DNA synthesis and of HCMV E and L genes

d Inhibition of IE2 transactivating properties identified by mechanistic studies

Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication

Beatrice Mercorelli,[1,4] Anna Luganini,[2,4] Giulio Nannetti,[1] Oriana Tabarrini,[3] Giorgio Palu`,[1] Giorgio Gribaudo,[2,5] and Arianna Loregian[1,5,*]

[1]Department of Molecular Medicine, University of Padua, 35121 Padua, Italy [2]Department of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy [3]Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy [4]Co-first author
[5]Co-senior author
*Correspondence:
arianna.loregian@unipd.it
http://dx.doi.org/10.1016/j.chembio
l.2015.12.012

SUMMARY

New targets for antiviral strategies are needed against human cytomegalovirus (HCMV), a major human pathogen. A cell-based screen aimed at finding inhibitors of the viral transcription factor Immediate-Early 2 (IE2) was performed in HCMV-infected cells expressing EGFP under the control of an IE2-induc-ible viral promoter. Screening of a library of bioactive small molecules led to the identification of several compounds able to inhibit EGFP expression and also HCMV replication with potency in the low-micro-molar range. Follow-up studies with four selected hits indicated that they all block viral DNA synthesis as well as viral Early and Late gene expression. Furthermore, mechanistic studies confirmed that the compounds specifically act via inhibition of IE2 transactivating activity, thus blocking viral Early gene expression and the progression of virus replica-tion. These results provide proof of concept for iden-tifying small molecules that modulate the activity of a microbial transcription factor to control pathogen replication.

INTRODUCTION

Viral transcription factors (vTFs) play pivotal roles not only in virus replication but also in virus-induced immunopathogenesis. This is achieved by their ability to both activate viral gene expression and to reprogram host pathways by interacting with cellular part-ners. For these reasons, vTFs represent attractive targets for drug discovery. However, traditionally, the identification of inhib-itors of both cellular and microbial TFs activity has been consid-ered very challenging, if not impossible. Indeed, TFs have been long considered ''undruggable'' targets since they lack intrinsic enzymatic activity, but in the recent years this idea has evolved and some modulators of TFs involved in pathogenic processes such as cancer progression and virus replication have been identified (Fletcher and Prochownik, 2015; Illendula et al., 2015; Makley and Gestwicki, 2013; Mousseau et al., 2012; Yan and Higgins, 2013). The Immediate-Early 2 (IE2) protein encoded by human cyto-megalovirus (HCMV) represents a prototypic vTF. In fact, it is an essential, multi-tasking protein that is involved in many events of the HCMV replication cycle (Mocarski et al., 2013). IE2 is required to activate the expression of viral Early (E) and Late (L) genes, negatively regulates its own expression by acting on the Major Immediate-Early promoter, and both activates and inhibits cellular gene expression (Marchini et al., 2001; Stinski and Petrik, 2008). Importantly, IE2 stimulates the expression of several proinflammatory genes in infected cells, deregulates the host cell cycle, first by inducing its progression and then by blocking it before S phase, and hampers the host immune responses (Stinski and Petrik, 2008; Taylor and Bresnahan, 2005, 2006). Taken together, there is compelling evidence

that IE2 is crucial for progression of the HCMV replicative cycle and plays a major role in HCMV pathogenesis and host immunomo-dulation (Mocarski et al., 2013). Thus, it represents a promising target for the development of new anti-HCMV agents (Mercorelli et al., 2011; Scholz et al., 2001); however, the identification and development of anti-IE2 molecules is hampered by the lack of a crystal structure of the protein, making the rational design of drugs an unfeasible strategy. HCMV is a ubiquitous beta-herpesvirus that infects more than 60% of the human population worldwide. HCMV is also a major human pathogen, which greatly affects HIV/AIDS patients, immunocompromised individuals, and transplant recipients, for whom the consequences of HCMV infection can cause severe diseases and be life-threatening (Nogalski et al., 2014). More-over, HCMV is one of the major causes of congenital defects in newborns (Manicklal et al., 2013). The available anti-HCMV drugs are used as both prophylactic and preemptive agents and are all targeted at the viral DNA polymerase, which is responsible for the replication of the viral genome (Boeckh et al., 2015). However, they suffer from several drawbacks including long-term toxicity, unfavorable pharmacokinetic prop-erties, and emergence of viral resistance. None of them has been licensed for the treatment of congenital infection; in addition, second-line therapeutics to manage drug-resistant viruses are inadequate. Despite the great efforts made in recent years, an effective and preemptive vaccine is still lacking (Fu et al., 2014); for all these reasons, there is a strong need for new anti-HCMV agents. Blocking viral replication before E gene expression has been proposed to be a valid antiviral approach that can also lead to the repression of a series of proinflamma-tory effects due to HCMV infection and responsible for virus-induced pathogenesis (Mercorelli et al., 2011; Scholz et al., 2001).

Figure 1. Cell-Based Screening Data

Each circle represents the mean % of EGFP expression for a given compound tested at 10 mM in duplicate during the primary (A) and secondary screen (B). Infected and DMSO-treated cells were considered as exhibiting 100% of EGFP expres-sion. The dashed line represents the arbitrary hit cutoff (50% of EGFP expression). In (B), among the compounds with two replicates below 50% of the EGFP expression threshold, active (green) com-pounds were distinguished from toxic (red) com-pounds. Compounds with the means above 50% were considered inactive (black)

To find inhibitors of the vTF IE2, we decided to apply a strategy of drug repurposing and to use a cell-based approach that selects compounds acting prior to or during the E gene expres-sion. We exploited an engineered HCMV-permissive cell line that stably expresses EGFP under the control of a prototypic E gene promoter of HCMV, i.e., the DNA polymerase *UL54* gene pro-moter (Luganini et al., 2008; Mercorelli et al., 2014a). This strat-egy led to the identification of a series of small molecules (one already approved by the U.S. Food and Drug Administration [FDA]) that block the replication of HCMV by inhibiting the activity of IE2 and could represent new candidates for anti-HCMV drug discovery. The approach described validates a cell-based screening strategy to find small-molecule modulators of the ac-tivity of a TF that could be potentially exploited for the identifica-tion of inhibitors of other TFs involved in pathogenic processes and for which the crystal structure has not yet been solved.

RESULTS

Optimization of a Cell-Based Assay for Small-Molecule Screening Targeting IE2
The U373-pUL54-EGFP (named UL54-2F7) and U373-pUL112-113-EGFP (named UL112-113-1B4) cell lines stably express EGFP under the control of the IE2-dependent *UL54* and *UL112-113* E promoters of HCMV, respectively (Luganini et al., 2008; Mercorelli et al., 2014a). We adapted this cell-based sys-tem to find compounds that act early in the HCMV replication cycle, using the IE2-dependent transactivation of an E promoter as a readout. A series of experiments were performed in order to determine the optimal cell line/cell density/multiplicity of infec-tion (MOI) combination that allowed a substantial and reliable in-duction of EGFP expression and a significant reduction in the presence of an active compound. The antisense oligodeoxynu-cleotide fomivirsen, which blocks IE2 expression (Azad et al.,1993), served as a positive control for the optimization and throughout the screening. As reported in Figure S1 in the Supple-mental Information, the maximal activation of EGFP expression was obtained with the combination of the UL54-2F7 cell line in-fected with HCMV at MOI of 0.5 plaque-forming units (pfu)/cell; under these conditions, EGFP expression levels in the presence of fomivirsen were comparable with those of the mock-infected cells (Figure S1). The calculated Z^0 factor from the positive and negative controls was 0.79 (Zhang et al., 1999); thus, we concluded that this experimental setting could be suitable for the screening and identification of inhibitors of IE2-dependent activation of viral E promoters. Moreover, to verify the progres-sion of HCMV replication beyond the IE2-induced EGFP expres-sion, we analyzed the expression of representative IE, E, and L HCMV proteins in U373 UL54-2F7 cells by western blot (WB) under the same conditions used for the screening. The results presented in Figure S2 clearly demonstrate that representative viral proteins are expressed in HCMV-infected U373 UL54-2F7 cells, thus indicating that progression of the HCMV replication cycle occurs under the conditions used for the screening.

Screening of the Spectrum Collection
The UL54-2F7 cell line was used for a primary screening of a total of 2,320 compounds, each at a concentration of 10 mM. As a positive control for the inhibition of EGFP expression, samples treated with fomivirsen were included in each plate. The Z^0 factors ranged between 0.59 and 0.76 and negligible in-terplate variability was observed. The criterion for an active compound was one that exhibited R50% reduction in the fluo-rescence units measured in the infected and DMSO-treated cells. In the primary screening, 125 compounds were identified that met this criterion (Figure 1A). These compounds were then retested by the same cell-based assay; however, when consid-ering the secondary screen results, we excluded those com-pounds that were clearly toxic (i.e., induced cell detachment) upon visual inspection of the cell monolayers before lysis at 72 hr post-infection (p.i.). This was done because the reduction in EGFP expression in those cases could most likely be due to cytotoxicity rather than to real inhibitory activity. Taking this into account, 38 molecules were reconfirmed as active in inhibiting EGFP expression (Figure 1B). Overall, we obtained a 1.6% hit

rate (38/2,320) when the limits of 50% inhibition in all the repli-cates and the absence of obvious toxicity were applied.

Table 1. Antiviral Activity and Cytotoxicity of the Hit Compounds in Follow-Up Testing

Compound (Sigma Cat. No.)	PubChem CID[a]	Antiviral Activity EC$_{50}$ (μM)[b]	Antiviral Activity EC$_{90}$ (μM)[c]	Cytotoxicity CC$_{50}$ (μM)[d]	SI[e]
(−)-Deguelin (D0817)	107935	1.3 ± 1.0	6.5 ± 1.6	>500	>357
Nitazoxanide (N0290)	41684	3.2 ± 0.6	11.8 ± 4.4	285 ± 86	102
Thioguanosine (858412)	2724387	1.2 ± 0.7	6.0 ± 2.1	>500	>357
Alexidine dihydrochloride (A8986)	102678	0.17 ± 0.04	0.44 ± 0.04	14.0 ± 8.5	88
Ganciclovir (G2536)	3454	3.4 ± 1.1	19.3 ± 1.1	>1,000	>294

See also Table S2.
[a]PubChem Compound ID. Data are available in PubChem Compound Database (http://pubchem.ncbi.nlm.nih.gov/compound).
[b]EC$_{50}$, compound concentration that inhibits 50% of plaque formation, as determined by PRAs against HCMV AD169 in HFF cells. Reported values represent the means ± SD of data derived from three experiments in duplicate.
[c]EC$_{90}$, compound concentration that inhibits 90% of plaque formation.
[d]CC$_{50}$, compound concentration that produces 50% of cytotoxicity, as determined by MTT assays in HFF cells. Reported values represent the means ± SD of data derived from two experiments in duplicate.
[e]SI, selectivity index (determined as the ratio between CC$_{50}$ and EC$_{50}$).

rate is higher than that expected for random high-throughput screenings (<0.1%–0.3%); however, this is most likely due to the fact that the Spectrum Collection is not a random library but is composed only of bioactive molecules. The list of the 38 compounds identified by the cell-based screens as able to inhibit HCMV-mediated induction of EGFP expression in UL54-2F7 cells is reported in Table S1 with their PubChem Compound Identification number and known bioactivities.

Hit Compounds Inhibit the Replication of HCMV in a Dose-Dependent Manner

To validate the anti-HCMV activity of the hits, plaque reduction assays (PRAs) with HCMV AD169 were performed with the 38 molecules from the library, along with the reference compound ganciclovir (GCV) as a control, and in parallel their cytotoxicities were tested by MTT assays. As reported in Table S1, 27 com-pounds exhibited a half maximal effective concentration (EC$_{50}$) < 10 mM in PRAs and 14 of them emerged with a selectivity index (SI) R 50. To select the compounds to be further charac-terized, a high SI value was then combined with information in PubMed and other sources about: (1) toxicological profile of the compound, (2) previous use in clinical trials in humans and in the pediatric setting, (3) pharmacokinetic properties, and (4) commercial availability. In addition, compounds with previously reported anti-HCMV activity likely not involving the inhibition of IE2 activity, i.e., berberine, clotrimazole, and papaverine, were excluded (Isler et al., 2005; Hayashi et al., 2007; Albrecht et al., 1987). This review process also revealed that some compounds selected by the screening may be useful as investigational tools but not for anti-HCMV drug repurposing. In fact, two of the most potent inhibitors, i.e., isorotenone and hexachlorophene (Table S1), have been reported to be associated with long-term toxicity (Evangelista de Duffard and Duffard, 1996; Moretto and Colo-sio, 2011), which is incompatible with their development as anti-HCMV therapeutics. At the end of this process, four hit compounds (Table 1), i.e., deguelin (DGN), nitazoxanide (NTZ), thioguanosine (TGN), and alexidine dihydrochloride (AXN), were selected and purchased for follow-up testing. PRAs and cytotoxicity assays were repeated with the selected hits and the EC$_{50}$ curves are reported in Figure 2. As reported in Table 1 and Figure 2, the anti-HCMV activity and the lack of significant

toxicity were reconfirmed for all of them, with EC_{50} values in the low-micromolar range. Since we observed that there was no difference between the EC_{50} values obtained in PRAs performed after pretreating the cells for 2 hr with test compounds before virus infection and EC_{50} values obtained in assays performed after adding the compounds 2 hr p.i. (data not shown), the com-pounds were added p.i. in all the experiments for follow-up testing.

PRAs were then repeated to assess the antiviral activity of the four selected hits against different strains of HCMV (including a clinical isolate) and viral strains resistant to ganciclovir or foscar-net (two drugs currently used in anti-HCMV therapy targeted at the viral DNA polymerase). As reported in Table S2, the EC_{50} values determined in these experiments were comparable with those obtained with the AD169 strain, suggesting that all the selected hits are broad-spectrum inhibitors of HCMV and likely block virus replication with a mechanism that differs from that of the viral DNA polymerase inhibitors.

Given the readout of the expression of EGFP at 72 hr p.i. in the screening, we performed time-of-addition studies in HCMV-in-fected U373 UL54-2F7 cells to determine which phase of the virus replication cycle was affected by the hit compounds. As shown in Figure S3, all the hit compounds act at a step sub-sequent to that affected by fomivirsen (an IE2 expression inhib-itor), since their addition led to loss of inhibitory effects from 8 to 24 hr p.i., a time frame compatible with the transition from IE to E phase during the HCMV replication cycle.

Hit Compounds Block the Onset of HCMV DNA Synthesis

To investigate the antiviral mechanism of the selected com-pounds further, we next tested the effects of the selected hits on viral DNA synthesis in HCMV-infected cells, a step subse-quent to viral E gene expression. To this aim, qPCR was per-formed from HCMV-infected human foreskin fibroblast (HFF) cells treated with DGN, NTZ, TGN, AXN, or WC5, a 6-aminoqui-nolone already reported to inhibit HCMV DNA synthesis, as a control (Loregian et al., 2010; Massari et al., 2013). As reported in Figure 3, HCMV DNA synthesis was inhibited by the treatment with all the hits tested and with WC5, as expected (Loregian et al., 2010). Thus, all the selected hits prevent the onset of HCMV DNA synthesis, demonstrating that they target an event in the HCMV replication cycle that precedes or takes place during virus DNA replication.

Figure 2. Dose-Dependent Inhibition of HCMV Replication by Hit Compounds Identified in the Cell-Based Screening

EC_{50} curves were obtained by infecting HFF cells with HCMV AD169 and then treating them with five different concentrations of DGN (A), NTZ (B), TGN (C), and AXN (D). Chemical structures of the hits are also reported. Calculated EC_{50}s are indicated. Data shown are the means $\pm$ SD of three experiments performed in duplicate.

Hit Compounds Halt the HCMV Replication Cycle Beyond the IE Phase

We investigated the effects of the hit compounds on the expres-sion of newly synthesized HCMV proteins by WB to further sup-port the above conclusion. To this aim, total cell extracts were prepared at various times p.i. from HCMV-infected HFF cells treated with DGN, NTZ, TGN, and AXN. The general transcription inhibitor actinomycin D (ActD) and WC5 were included as con-trols. Then, the extracts were analyzed for their content of repre-sentative Immediate-Early (IE1 and IE2), Early (UL44), and Late (UL55 and UL99) proteins. As expected from its mode of action, no viral proteins were detected in the ActD-treated cells (Fig-ure 4). In keeping with previous reports (Loregian et al., 2010; Mercorelli et al., 2014b), the expression of the E protein UL44 was strongly reduced by WC5 at 48 hr p.i. (Figure 4), while it had no effect on IE protein synthesis. When the selected hits were considered, none of the compounds significantly affected the expression of IE proteins at any of the time points considered (Figure 4A–4D). In contrast, treatment with DGN, NTZ, TGN, and AXN reduced UL44 expression in a manner similar to WC5 (Figure 4). Moreover, a strong inhibitory effect on the expression of L proteins (UL55 and UL99) was observed for all the tested mol-ecules at 72 hr p.i. (Figure 4). Overall, these results showed that DGN, NTZ, TGN, and AXN affect HCMV replication by acting at an E phase of the viral replicative cycle after the IE protein

expression, but before E and L protein expression, in keeping with the results obtained from the time-of-addition experiments (Figure S3) and the studies on viral DNA synthesis (Figure 3).

Hit Compounds Inhibit IE2-Dependent Transactivation of HCMV E Promoters
The results presented above and the features of the cell-based assay employed for the screening suggested that the selected hit compounds could act by inhibiting IE2-mediated E gene transactivation. To test this hypothesis, the indicator cell line UL54-2F7, already used for the screening, was transduced with adenoviral vectors either expressing IE2 (AdVIE2) or *Escherichia coli* b-galactosidase (AdVLacZ) as a control (Mercorelli et al., 2014b; Figure S4). Subsequently, cells were treated with DNG, NTZ, TGN, and AXN to examine their effects on EGFP expres-sion. WC5 and fomivirsen were included as controls. As shown in Figure 5A (left), IE2 overexpression resulted in EGFP expres-sion; in contrast, strong inhibition of EGFP expression was


Figure 3. Treatment with the Hit Compounds Blocks Viral DNA Synthesis in HCMV-Infected Cells
HFFs were infected with HCMV and then treated with test compounds or DMSO as a control. At 24 and 72 hr p.i., total DNA was extracted and qPCR was performed with appropriate *IE2* and b-*globin* primers. HCMV genomic copies were normalized to the cellular b-*globin* gene copies. Data shown are the means ± SD of three independent experiments performed in duplicate. $*p < 0.05$; $**p < 0.001$ versus calibrator sample (HCMV-infected cells + DMSO) in a paired t test.

observed in the cells treated with all test compounds. These re-sults were confirmed by a quantitative microscopic analysis of EGFP-positive cells that showed a 70%–80% reduction in EGFP expression upon treatment of IE2 overexpressing cells with test compounds (Figure 5A, right), similar to that obtained with WC5 and fomivirsen. A comparable inhibitory activity of the hit compounds on IE2-dependent transactivation was also observed with the *UL112-113* E gene promoter (Figure 5B), thus indicating interference with the IE2-dependent transactiva-tion of two different E gene promoters of HCMV.
We examined the effects of the four selected compounds on *UL54* gene promoter activity in a different format of cell-based assay to further support this conclusion. To this end, a luciferase reporter plasmid containing the entire *UL54* promoter (pUL54– 0.4) was first transfected into HFFs that were then transduced with AdVIE2 or AdVLacZ as a control. Two hours later, cells were treated with the selected hits (and WC5 and fomivirsen as controls) and the luciferase activity was assessed after 48 hr. As reported in Figure 5C, in agreement with the results described above (Figure 5A), IE2-dependent transactivation of the *UL54* promoter was inhibited by the treatment with all the compounds tested. Noteworthy, similarly reduced levels of reporter gene activity were observed when the transfection-transduction assays were performed using a luciferase reporter construct driven

by a minimal *UL54* promoter (pUL54–0.15, with 0.15 kbp upstream from the transcription start site, Figure 5C). Altogether, these results indicate that the selected hits target IE2-dependent transactivation of viral E gene promoters.

IE2 Inhibitors Do Not Interfere with the Transactivating Activity of Another HCMV TF

To examine the specificity of the inhibitory effect of the four hits on the IE2 transactivating activity, we investigated their effects on the activity of another HCMV-encoded vTF, i.e., the Immediate-Early 1 (IE1) protein. IE1 is the other major protein product of the HCMV *MIE* locus and shares the first 85 amino acids with IE2 (Stinski and Petrik, 2008). In a previous study, we demonstrated that the cellular human thymidylate synthase (*TS*) gene promoter is transactivated by both HCMV and the IE1 protein in quiescent fibroblasts (Gribaudo et al., 2002). Thus, we investigated the effects of the hit compounds on the IE1-dependent transcriptional activation of *TS* promoter. As shown in Figure 6, in transient transfection experiments performed in HFFs, all the compounds tested did not affect IE1-dependent transactivation of human *TS* promoter (Gribaudo et al., 2002). The IE2-specific inhibitor WC5, used as a control, was ineffective in interfering with the IE1-mediated activation of the cellular gene promoter, as expected (Mercorelli et al., 2014b). Together, these results indicated that the four selected hit compounds are endowed with an inhibitory activity that is specific for IE2 over IE1.

DISCUSSION

In this article, we describe a target-based drug repurposing screen to identify molecules able to inhibit the activity of an essential transcription factor encoded by HCMV and hence pathogen replication. IE2 has emerged as an attractive antiviral target for new anti-HCMV drug discovery (Mercorelli et al., 2011; Scholz et al., 2001), and we recently identified a small molecule, the 6-aminoquinolone WC5, as a specific inhibitor of IE2 functions essential for optimal viral replication (Mercorelli et al., 2009; Loregian et al., 2010; Mercorelli et al., 2014b). The identification of the mechanism of action of this compound gave us the proof of principle that IE2 is a druggable target and that the modulation of its activity by small molecules is possible. Not only is IE2 the major transactivator of viral E gene expression but it also establishes a strict interplay with several cellular pathways that it modulates and hijacks to pro-mote HCMV replication in the host cell. For this reason, we thought that a drug repurposing approach could successfully lead to the discovery of new IE2 inhibitors, and therefore we screened a small-molecule library that consists of 2,320 bioac-tive molecules including all FDA-approved drugs.

The screening assay was based on the exploitation of an HCMV-permissive cell line stably transfected with an EGFP re-porter under the control of the promoter of the prototypic viral E gene *UL54*, which encodes DNA polymerase. Upon infection with HCMV, EGFP expression is induced by IE2-dependent transactivation of *UL54* promoter. Treatment with compounds able to interfere with this event or upstream viral functions leads to a quantifiable reduction in EGFP expression. From the initial screening, 125 compounds emerged as able to reduce IE2-induced EGFP expression from the *UL54* promoter. We then retested these compounds by the same assay and finally obtained 38 molecules to be evaluated for their antiviral activity against HCMV. Therefore, PRAs and in parallel cytotox-icity assays were performed in HFF cells. Interestingly, we noticed that some of the compounds showing anti-HCMV activity belong to the same chemotype (e.g., isorotenone and its derivatives DGN, apotoxicarol and a-toxicarol; Table S1). Moreover, we also found compounds with an already reported early anti-HCMV activity, such as berberine (Hayashi et al., 2007), clotrimazole (Isler et al., 2005), and papaverine (Albrecht et al., 1987) (Table S1), thus validating our experimental approach. The fact that other known anti-HCMV drugs included

Figure 4. Effects of Hit Compounds on the Expression of Representative HCMV IE, E, and L Proteins

in the library that have a target other than IE2 (e.g., DNA poly-merase inhibitors) were not selected by our screening indicates that the strategy was specific for the identification of IE2 inhib-itors (or compounds acting upstream) and not of any HCMV inhibitor.

For the characterization of the antiviral activity, we selected only four hits, an FDA-approved drug (NTZ) and three drugs un-der development (DGN, TGN, and AXN). Other compounds with a very promising SI (e.g., hexachlorophene and isorote-none; Table S1) were excluded since they are not suitable for clinical use in anti-HCMV therapy due to their long-term toxicity. The possibility of excluding some compounds a priori, although very active, based on the available information is one of the advantages of the drug repurposing approach. It is also important to underline, however, that the active compounds that were not selected as drug candidates could represent use-ful research tools to uncover molecular mechanisms of HCMV biology, since they point out possible cellular pathways that might be involved in virus replication and thus could be a start-ing point for other researchers in the scientific community. All four selected hits were reordered separately and their antiviral activity was confirmed not only against the HCMV AD169 strain

Figure 4. Effects of Hit Compounds on the Expression of Representative HCMV IE, E, and L Proteins
HFFs were infected with HCMV and then treated with test compounds i.e., DGN (A), NTZ (B), TGN (C), or AXN (D), or DMSO as a control. At the indicated times p.i., total cell extracts were pre-pared and analyzed by WB with anti-IEA (IE1 and IE2), anti-UL44, anti-UL55, and anti-UL99 anti-bodies.

Samples treated with either ActD or WC5 were also included as controls for inhibition of protein expression at 24 hr and 48 hr p.i., respectively. Tubulin immunodetection served as a loading control.

but also against a panel of other HCMV strains, suggesting broad-spectrum anti-HCMV activity for all of them. When the effects on viral DNA synthesis and viral protein expression were analyzed, we observed that all four hits did not affect the expression of IE pro-teins, while viral DNA synthesis as well as the E and L gene products were significantly reduced. These results sug-gested that the IE2-dependent transacti-vation of E genes could be a target of the four compounds. Indeed, we provided strong evidence that the four hits act via the inhibition of an IE2-dependent activity (i.e., transactivation of viral E genes), thus preventing progression of the HCMV replication cycle. Figure 5 summarizes the mechanistic analysis of the anti-IE2 activity of the four hits. We clearly demonstrated by means of trans-fection-transduction experiments with a recombinant adenovirus expressing IE2 alone that the hits block IE2-dependent transactivation of E genes in the absence of any other HCMV protein and in various experimental set-tings. Importantly, the lack of interference with the transactivat-ing activity of another vTF encoded by HCMV, i.e., IE1, which shares 85 N-terminal residues with IE2 (Stinski and Petrik, 2008), strongly supports the specificity of the hit compounds toward IE2-dependent transactivation. During the preparation of this manuscript, an article reporting the screening of an older, smaller version of the Spectrum Collection to find early inhibitors of HCMV was published (Gardner et al., 2015). Our assay was conceived to find inhibitors of IE2-dependent E gene activation, while the assay described by Gardner et al. was designed to find compounds that act by inhibiting IE2 expression, an event that precedes viral E gene expression. This difference can thus explain why the hits identified in our screening were not selected by the other approach (Gardner et al., 2015). On the other hand, the two hits reported by Gard-ner et al., convallatoxin and podofillox, fall into the list of the compounds that we excluded due to their toxicity at 10 mM. This is in agreement with the fact that these two compounds were reported to have half maximal cytotoxicity concentration (CC50) values around 5 mM (Gardner et al., 2015); thus our test concentration was 2-fold higher that their CC50.

The results presented here provide evidence of the feasibility of targeting the activity of a virus-encoded TF to block HCMV replication. This represents a significant conceptual advance over previously identified anti-HCMV compounds, since they were targeted mainly at viral enzymes. We have employed and successfully validated an assay for small-molecule screening that uses the transactivation of an essential viral gene by a spe-cific virus-encoded TF as readout for the screening. Although the library used in this study has a small size, our assay is potentially suitable also for high-throughput screening campaigns, since it was relatively rapid, robust, easy to perform, and reliably quan-titative. A similar strategy could be applied for the identification of inhibitors of other TFs involved in microbial pathogenic pro-cesses. TFs have long been considered ''undruggable'' targets for therapeutic development; however, this study and others (Fletcher and Prochownik, 2015; Illendula et al., 2015; Mousseau et al., 2012; Yan and Higgins, 2013) provide the evidence that small-molecule modulators of TF activity can be identified by screening.

Small molecules that modulate IE2 activity might act by different mechanisms, for example, by disrupting the interac-tion between IE2 and its cellular/viral partners, by interfering with IE2 post-translational modifications required for its trans-activating functions, and by indirectly affecting host molecular pathways intercepted by IE2 and essential to create a cellular environment conducive to HCMV replication. Since all four hits have been already reported to have effects on cellular pathways, their antiviral activity could be due most likely to interference with those pathways in HCMV-infected cells that are required for the switch from the IE to E phase. For instance, DGN, a natural rotenoid derivative, is a known inhib-itor of activated Akt, Hsp90, and client proteins and is under investigation as an antitumoral agent (Wang et al., 2013; Oh et al., 2007). Being a multifunctional signal transduction inhib-itor, DGN could interfere with several of the cellular and viral pathways required for the correct progression of HCMV repli-cation. To corroborate this, it has been demonstrated that phosphatidylinositol 3-kinase (PI3K)/Akt inhibitors can block herpesvirus infection (Liu and Cohen, 2015). TGN is an analog of guanosine and has been reported to inactivate cellular GTPase activity by depleting GTP levels. GTP-binding partners such as Rheb and Rac proteins are required for efficient HCMV replication and indeed VX-497, an inhibitor of GTP/dGTP biosynthesis, demonstrated anti-HCMV activity (Markland et al., 2000). Moreover, GTP-Rheb activity is necessary for mTOR activation, which is required for efficient HCMV replica-tion (Moorman and Shenk, 2010). AXN is an antibiotic and a selective inhibitor of the mitochondrial phosphatase Ptpmt1. It was reported that treatment with AXN reprograms cellular metabolism from aerobic activity to glycolysis leading to hy-peractivation of 5^0 AMP-activated protein kinase (AMPK) (Liu et al., 2015). The hyperactivation of AMPK could be detri-mental for HCMV replication, since it counteracts the PI3K/ Akt/mTOR pathway. The only FDA-approved drug among the selected hits, NTZ, was initially developed as an oral antipara-sitic agent against protozoan and helminthic infections, but it also demonstrated antibacterial activity on *Mycobacterium tuberculosis*. More recently, NTZ emerged as a first-in-class broad-spectrum antiviral agent, since it showed activity against 20 different RNA and DNA viruses but, up to this report, not against HCMV, by interfering with the cellular func-tions necessary for viral replication (Rossignol et al., 2009; Sta-chulski et al., 2011; La Frazia et al., 2013; Rossignol, 2014). Currently, NTZ is in phase 3 clinical trials for treating influenza virus infection (Haffizulla et al., 2014). Moreover, NTZ pro-motes autophagy, activates AMPK, and interferes with the activity of several kinases such as PI3K/Akt/mTOR and mitogen-activated protein kinase (MAPK) signaling pathways (Senkowski et al., 2015; Lam et al., 2012; Fan-Minogue et al., 2013). Furthermore, it depletes ATP-sensitive intracel-lular Ca^{2+} inducing mild ER stress (Ashiru et al., 2014). HCMV, like other viruses, induces viral and cellular kinases and phosphatases at appropriate times in order to mediate correct temporal expression of viral genes during the course of infection. The activity of TFs is regulated within the cell by different mechanisms such as intracellular localization and post-translational modifications that can induce confor-mational changes and/or modification of local charge and affect the ability of TFs to interact with other proteins. We thus investigated whether the antiviral effect of NTZ against HCMV IE2 could be due to altered localization of the TF, since no difference in IE2 expression was detected following NTZ treatment (Figure 4), while inhibition of IE2-dependent transac-tivation of viral E promoters was observed (Figure 5). By immu-nofluorescence analysis, we observed that in infected cells treated with NTZ, IE2 nuclear localization was altered since the protein was partially retained in the cytoplasm (Figure S5). A possible explanation of the effect of NTZ on IE2 nuclear localization could be that it interferes with the correct and time-regulated phosphorylation status of IE2, resulting in altered conformation of the protein and/or impairment in pro-tein-protein interactions. In fact, the nuclear localization of some HCMV proteins, such as the DNA polymerase processiv-ity factor UL44, is regulated by phosphorylation (Alvisi et al., 2011). Since NTZ is known to intercept several kinase path-ways including MAPKs, that have been suggested to be involved in IE2 phosphorylation (Harel and Alwine, 1998; Bar-rasa et al., 2005), the anti-HCMV activity of NTZ might be due, at

least in part, to altered post-translational modifications of IE2, but this hypothesis has to be tested in the future. In keeping with this, the major protein-protein interaction domains of IE2 colocalize with domains of IE2 that are phos-phorylated (Lukac et al., 1997), and mutations of certain phos-phorylated residues of IE2 or in vitro phosphorylation of IE2 have been related to the modulation of its transactivating properties and its ability to interact with protein partners (Bar-rasa et al., 2005; Waheed et al., 1998).

Dissection of the mode of action of the hits against IE2 and HCMV replication will be the subject of our future work. Regard-less, the IE2 inhibitors that we identified, as well as the other com-pounds with anti-HCMV activity reported in this study, could be starting points for new anti-HCMV drug discovery. In particular, NTZ, which is already used in clinical practice, could be rapidly considered for clinical evaluation for the treatment of HCMV-associated pathogenic conditions as well as prophylactic agents to prevent HCMV reactivation in high-risk patients.

UL54-2F7

A

UL112/113-1B4

B

C


Relative Luciferase Units (RLU)

Figure 6. Hit Compounds Do Not Interfere with the IE1-Dependent Transactivation of the Cellular Thymidylate Synthetase Gene Promoter

HFFs were transfected with a luciferase reporter plasmid containing a portion of the human thymidylate synthetase promoter (phTS-243/+30) alone, or co-transfected with a plasmid expressing HCMV IE1 (pSGIE72), or the pSG5 empty vector, and then treated with test compounds or DMSO as a control. At 48 hr post-transfection, the luciferase activity was determined. Data shown are the means ± SD of three independent experiments performed in duplicate.

SIGNIFICANCE

HCMV is a major human pathogen and new drugs are needed to manage congenital infections and the emergence of strains resistant to the currently available anti-DNA poly-merase drugs. Using a target-based screening assay, a few small-molecule inhibitors of HCMV-encoded IE2 have been discovered. These HCMV inhibitors prevent viral DNA syn-thesis, E and L gene expression, as well as the IE2-depen-dent transactivation of viral E promoters. These compounds could be exploited in anti-HCMV drug development but could also represent useful tools in elucidating the molecu-lar mechanisms of HCMV replication. Importantly, the drug repurposing approach that we applied resulted in the identi-fication of a molecule, NTZ, that is already an FDA-approved therapeutic; moreover, NTZ is also currently being evaluated in phase 3 clinical trials as a new anti-influenza candidate drug. Thus, its further clinical evaluation is strongly recom-mended. The inhibitors described here could be the first anti-HCMV small molecules specifically targeting IE2 func-tions and could fill the gap in the current anti-HCMV thera-peutic options by DNA polymerase inhibitors. Our results, furthermore, open the way to the study of new cellular path ways that could be essential for virus replication and eventu-ally reveal new drug targets.

EXPERIMENTAL PROCEDURES

Cells and Viruses
U373-pUL54-EGFP (clone 2F7) and U373-pUL112-113 (clone 1B4) cells, which stably express EGFP under the control of the IE2-dependent early *UL54* and *UL112-113* promoters of HCMV, respectively (Luganini et al., 2008), were grown in Dulbecco modified Eagle's medium (DMEM; Life Tech-nologies) with 10% fetal bovine serum (FBS; Life Technologies), 100 U/ml peni-cillin, 100 mg/ml streptomycin sulfate (P/S; Life Technologies), and 750 mg/ml of G418 (Life Technologies). HFF cells were cultured in DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM glutamine, and P/S. HCMV strain AD169 (VR-538) was purchased from the American Type Culture Collection. HCMV strains resistant to antiviral drugs (all obtained from the

NIH AIDS Research and Reference Reagent Program) were previously described (Mer-corelli et al., 2009). HCMV TB40-UL32-EGFP (kindly provided by C. Sinzger, University of Ulm, Germany) was previously described (Sampaio et al., 2005) as well as HCMV VR1814 (kindly provided by G. Gerna, IRCCS Policlinico San Matteo, Pavia, Italy) recovered from a cervical swab from a pregnant woman (Revello et al., 2001). Recombinant adenoviruses expressing HCMV IE2 or *E. coli* b-galactosidase (LacZ) were previously described (Mercorelli et al., 2014b).

Plasmids

The pUL54-luciferase indicator plasmids pUL54–0.4 and pUL54–0.15, con-taining *UL54* promoter-derived sequences were previously reported (Gariano et al., 2012). The pSGIE72, an IE1 expression construct, was generated as described (Klucher et al., 1993). The luciferase indicator construct phTS-243/+30 contains a portion of the promoter of the human thymidylate synthase gene (*TS*) (243 and +30 relative to the AUG start codon) (Gribaudo et al., 2002). The pRL-TK vector expressing *Renilla* luciferase was purchased from Promega.

Spectrum Collection and Chemical Substances

The Spectrum Collection was purchased from Microsource Discovery System. It consists of 2,320 bioactive molecules, including 1,040 FDA-approved drugs, dissolved in 100% DMSO at 10 mM and was stored at 20 C. Fomivirsen (ISIS 2922) was synthesized by Metabion International AG. The anti-HCMV 6-ami-noquinolone WC5 was previously described (Mercorelli et al., 2009). All the other chemical substances including the hits for the follow-up studies were purchased from Sigma-Aldrich.

Set Up of a Cell-Based EGFP Expression Reporter Assay

The detailed description of the optimization of the cell-based assay for the screening is reported in the Supplemental Experimental Procedures.

Screening Protocol and Data Analysis

U373 UL54-2F7 cells seeded the day before at 2 3 10^4 cells per well in 96-well plates were pretreated with test compounds for 2 hr prior to infection with HCMV AD169 at an MOI of 0.5 pfu/cell. The compounds of the Spectrum Collection were screened in duplicate in two independent plates at a fixed con-centration of 10 mM. Control wells with mock-infected cells and infected cells treated with either 0.01% DMSO or 5 mM fomivirsen were included in each plate during the screening. After the infection, cells were incubated with the

Figure 5. Hit Compounds Block the IE2-Dependent Transactivation of HCMV E Promoters

(A and B) UL54-2F7 (A) or UL112-113-1B4 (B) cells were transduced with AdVIE2 or with AdVLacZ and then treated with test compounds or DMSO as a control. Representative confocal microscopy images (EGFP) acquired at 72 hr post-transduction (p.t.) are shown (left). At the same time, confocal microscopy was used to quantify the percentage of EGFP-expressing cells in 20 different fields. DMSO-treated transduced cells were considered 100% (right).

(C) HFFs were transfected with luciferase reporter plasmids pUL54–0.4 or pUL54–0.15 and after 24 hr were transduced with AdVIE2 or AdVLacZ. Then, cells were treated with test compounds or DMSO as a control. At 48 hr p.t., luciferase expression was determined and the transcriptional activity was expressed as relative luciferase units.

Data shown are the means ± SD of three experiments performed in duplicate. The results presented in all panels were analyzed with Bonferroni post-test correction for multiple comparisons. ***p < 0.001 versus calibrator sample (AdVIE2 + DMSO).

compounds for 72 hr at 37 C. Finally, cells were lysed and EGFP expression was determined as described in the Supplemental Experimental Procedures. The total screening time for each compound was approximately 5 days. The quality of the screening assay was determined as described in (Zhang et al., 1999) by calculating the Z^0 score of each plate according to Equation 1:

$$Z^0 = 1 \quad (j3s_{C+} + 3s_C \ j/j3m_{C+} \quad 3m_C \ j), \quad \text{(Equation 1)}$$

where C+ are the fluorescence units in the cells treated with fomivirsen and C are the fluorescence units in the DMSO-treated cells. For hits selection, a cut-off of 50% of inhibitory activity was arbitrarily set. The inhibitory activity of each compound was determined according to Equation 2.

$$\% \ \text{Activity} = (FU_{Compound}/FU_C \ ) 3 \ 100, \quad \text{(Equation 2)}$$

where FU are the fluorescence units.

Nontoxic compounds with R50% inhibitory activity in two rounds of screening were selected for further characterization.

Antiviral and Cytotoxicity Assays
PRAs and cytotoxicity assays were performed as previously described (Lore-gian and Coen, 2006).

Quantitative Real-Time PCR
To analyze the effects of the hits on viral DNA synthesis, HFFs were seeded at a density of $1.5 \ 3 \ 10^5$ per well in 24-well plates. The next day, cells were infected with HCMV AD169 at an MOI of 0.5 pfu/cell and, following virus adsorption (2 hr at 37 C), they were incubated with 20 mM DGN, 30 mM NTZ, 15 mM TGN, 2 mM AXN, or 50 mM WC5 as a control. At 24 and 72 hr p.i., cells were collected and total DNA and the levels of viral DNA were then determined by qPCR and normalized to the cellular b-*globin* gene copies (Loregian et al., 2010; Mengoli et al., 2004). The oligonucleotide sequences used for the qPCR experiments are reported in the Supplemental Information (Table S3).

Western Blot Analysis
HFFs were seeded in 6-well plates at a density of $3 \ 3 \ 10^5$ cells per well. The next day, cells were infected with HCMV AD169 at an MOI of 0.5 pfu/cell and, following virus adsorption, cells were treated with 20 mM DGN, 30 mM NTZ, 15 mM TGN, 2 mM AXN, or with an equal volume of DMSO (0.1% v/v). Infected samples treated with either 5 mg/ml ActD or 50 mM WC5 were also included. Cells extracts collected at 24, 48, and 72 hr p.i. were prepared and analyzed as previously described (Bronzini et al., 2012). The list of primary antibodies used in this study is reported in the Supplemental Informa-tion (Table S4).

Cell Transfections and Adenoviral Transductions
For transduction experiments, UL54-2F7 and UL112-113-1B4 cells were seeded at $4.5 \ 3 \ 10^4$ cells per well onto glass coverslips in 24-well plates. Cells were transduced with either AdVIE2 or AdVLacZ (MOI of 40 pfu/cell) for 2 hr at 37 C, and then treated with 20 mM DGN, 30 mM NTZ, 15 mM TGN, 2 mM AXN, 50 mM WC5, 5 mM fomivirsen, or 0.1% v/v of DMSO. At 72 hr p.i., cells were fixed and mounted with mounting medium (Sigma). Samples were observed with a 203 objective under an Olympus IX70 inverted laser scanner confocal microscope equipped with FluoView 300 software.

For transfection and transduction experiments, HFFs were seeded on 24-well plates at $4.5 \ 3 \ 10^4$ cells per well and co-transfected the following day using calcium phosphate (CellPhect Transfection Kit, GE Healthcare) with 0.9 mg of pUL54–0.4 or pUL54–0.15 plasmid, and with 0.1 mg of pRL-TK plasmid as a control to assess transfection efficiency. At 24 hr post-trans-fection, cells were transduced with either AdVIE2 or AdVLacZ at an MOI of 10 pfu/cell for 2 hr at 37 C, and then

treated with 20 mM DGN, 30 mM NTZ, 15 mM TGN, 2 mM AXN, 50 mM WC5, or 0.1% DMSO (v/v) for 48 hr before deter-mination of luciferase activity.

For transfection experiments in HFFs, cells were co-transfected with cal-cium phosphate with 0.3 mg of phTS-243/+30 plasmid, 0.6 mg of pSGIE72, or pSG5 empty vector, and with 0.05 mg of pRL-TK plasmid. At 18 hr post-transfection, cells were washed and then maintained in low-serum medium and treated with 20 mM DGN, 30 mM NTZ, 15 mM TGN, 2 mM AXN, 50 mM WC5, or 0.1% v/v of DMSO for 48 hr before determination of luciferase activity. For all the experiments, the values were normalized by dividing the values obtained for firefly luciferase by the values obtained for *Renilla* luciferase and expressed as relative luciferase units.

Statistical Analysis

All statistical tests were performed using GraphPad Prism version 5.0 for Win-dows. Data are presented as the means ± SDs of at least two experiments in duplicate.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, five figures, and four tables and can be found with this article online at http://dx.doi.org/10.1016/j.chembiol.2015.12.012.

AUTHOR CONTRIBUTIONS

B.M. and A. Luganini conceived and performed experiments, analyzed data, wrote the paper, and edited the paper. G.N. performed experiments. O.T. pro-vided reagents. G.P., G.G., and A. Loregian designed experiments, wrote the paper, and edited the paper.

ACKNOWLEDGMENTS

REFERENCES

Albrecht, T., Lee, C.H., Speelman, D.J., and Steinsland, O.S. (1987). Inhibition of cytomegalovirus replication by smooth-muscle relaxing agents. Proc. Soc. Exp. Biol. Med. *186*, 41–46.

Alvisi, G., Marin, O., Pari, G., Mancini, M., Avanzi, S., Loregian, A., Jans, D.A., and Ripalti, A. (2011). Multiple phosphorylation sites at the C-terminus regulate nuclear import of HCMV DNA polymerase processivity factor ppUL44. Virology *417*, 259–267.

Ashiru, O., Howe, J.D., and Butters, T.D. (2014). Nitazoxanide, an antiviral thia-zolide, depletes ATP-sensitive intracellular Ca(2+) stores. Virology *462-463*, 135–148.

Azad, R.F., Driver, V.B., Tanaka, K., Crooke, R.M., and Anderson, K.P. (1993). Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. *37*, 1945–1954.

Barrasa, M.I., Harel, N.Y., and Alwine, J.C. (2005). The phosphorylation status of the serine-rich region of the human cytomegalovirus 86-kilodalton major im-mediate-early protein IE2/IEP86 affects temporal viral gene expression. J. Virol. *79*, 1428–1437.

Boeckh, M., Murphy, W.J., and Peggs, K.S. (2015). Recent advances in cyto-megalovirus: an update on pharmacologic and cellular therapies. Biol. Blood Marrow Transplant *21*, 24–29.

Bronzini, M., Luganini, A., Dell'Oste, V., De Andrea, M., Landolfo, S., and Gribaudo, G. (2012). The US16 gene of human cytomegalovirus is required for efficient viral infection of endothelial and epithelial cells. J. Virol. *86*, 6875–6888.

Evangelista de Duffard, A.M., and Duffard, R. (1996). Behavioral toxicology, risk assessment, and chlorinated hydrocarbons. Environ. Health Perspect. *104*, 353–360.

Fan-Minogue, H., Bodapati, S., Solow-Cordero, D., Fan, A., Paulmurugan, R., Massoud, T.F., Felsher, D.W., and Gambhir, S.S. (2013). A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. Mol. Cancer Ther. *12*, 1896–1905.

Fletcher, S., and Prochownik, E.V. (2015). Small-molecule inhibitors of the Myc oncoprotein. Biochim. Biophys. Acta *1849*, 525–543.

Fu, T.M., An, Z., and Wang, D. (2014). Progress on pursuit of human cytomeg-alovirus vaccines for prevention of congenital infection and disease. Vaccine *32*, 2525–2533.

Gardner, T.J., Cohen, T., Redmann, V., Lau, Z., Felsenfeld, D., and Tortorella, D. (2015). Development of a high-content screen for the identification of inhib-itors directed against the early steps of the cytomegalovirus infectious cycle. Antiviral. Res. *113*, 49–61.

Gariano, G.R., Dell'Oste, V., Bronzini, M., Gatti, D., Luganini, A., De Andrea, M., Gribaudo, G., Gariglio, M., and Landolfo, S. (2012). The intracellular DNA sensor IFI16 gene acts as restriction factor for human cytomegalovirus replica-tion. PLoS Pathog. *8*, e1002498.

Gribaudo, G., Riera, L., Rudge, T.L., Caposio, P., Johnson, L.F., and Landolfo, S. (2002). Human cytomegalovirus infection induces cellular thymidylate syn-thase gene expression in quiescent fibroblasts. J. Gen. Virol. *83*, 2983–2993.

Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Bardin, M., and Rossignol, J.F. (2014). Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect. Dis. *14*, 609–618.

Harel, N.Y., and Alwine, J.C. (1998). Phosphorylation of the human cytomeg-alovirus 86-kilodalton immediate-early protein IE2. J. Virol. *72*, 5481–5492.

Hayashi, K., Minoda, K., Nagaoka, Y., Hayashi, T., and Uesato, S. (2007). Antiviral activity of berberine and related compounds against human cytomeg-alovirus. Bioorg. Med. Chem. Lett. *17*, 1562–1564.

Illendula, A., Pulikkan, J.A., Zong, H., Grembecka, J., Xue, L., Sen, S., Zhou, Y., Boulton, A., Kuntimaddi, A., Gao, Y., et al. (2015). Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFbeta-SMMHC delays leukemia in mice. Science *347*, 779–784.

Isler, J.A., Maguire, T.G., and Alwine, J.C. (2005). Production of infectious hu-man cytomegalovirus virions is inhibited by drugs that disrupt calcium homeo-stasis in the endoplasmic reticulum. J. Virol. *79*, 15388–15397.

Klucher, K.M., Sommer, M., Kadonaga, J.T., and Spector, D.H. (1993). In vivo and in vitro analysis of transcriptional activation mediated by the human cyto-megalovirus major immediate-early proteins. Mol. Cell. Biol. *13*, 1238–1250.

La Frazia, S., Ciucci, A., Arnoldi, F., Coira, M., Gianferretti, P., Angelini, M., Belardo, G., Burrone, O.R., Rossignol, J.F., and Santoro, M.G. (2013). Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation. J. Virol. *87*, 11096–11106.

Lam, K.K.Y., Zheng, X., Forestieri, R., Balgi, A.D., Nodwell, M., Vollett, S., Anderson, H.J., Andersen, R.J., Av-Gay, Y., and Roberge, M. (2012). Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intra-cellular proliferation of *Mycobacterium tuberculosis*. PLoS Pathog. *8*, e1002691.

Liu, X., and Cohen, J.I. (2015). The role of PI3K/Akt in human herpesvirus infec-tion: from the bench to the bedside. Virology *479-480*, 568–577.

Liu, X., Zheng, H., Yu, W.M., Cooper, T.M., Bunting, K.D., and Qu, C.K. (2015). Maintenance of mouse hematopoietic stem cells ex vivo by reprogramming cellular metabolism. Blood *125*, 1562–1565.

Loregian, A., and Coen, D.M. (2006). Selective anti-cytomegalovirus com-pounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. Chem. Biol. *13*, 191–200.

Loregian, A., Mercorelli, B., Muratore, G., Sinigalia, E., Pagni, S., Massari, S., Gribaudo, G., Gatto, B., Palumbo, M., Tabarrini, O., et al. (2010). The 6-amino-quinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein. Antimicrob. Agents Chemother. *54*, 1930–1940.

Luganini, A., Caposio, P., Mondini, M., Landolfo, S., and Gribaudo, G. (2008). New cell-based indicator assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral immediate-early 2 protein activity. J. Appl. Microbiol. *105*, 1791–1801.

Lukac, D.M., Harel, N.Y., Tanese, N., and Alwine, J.C. (1997). TAF-like func-tions of human cytomegalovirus immediate-early proteins. J. Virol. *71*, 7227– 7239.

Makley, L.N., and Gestwicki, J.E. (2013). Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions. Chem. Biol. Drug Des. *81*, 22–32.

Manicklal, S., Emery, V.C., Lazzarotto, T., Boppana, S.B., and Gupta, R.K. (2013). The ''silent'' global burden of congenital cytomegalovirus. Clin. Microbiol. Rev. *26*, 86–102.

Marchini, A., Liu, H., and Zhu, H. (2001). Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. J. Virol. *75*, 1870–1878.

Markland, W., McQuaid, T.J., Jain, J., and Kwong, A.D. (2000). Broad-spec-trum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a compari-son with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. *44*, 859–866.

Massari, S., Mercorelli, B., Sancineto, L., Sabatini, S., Cecchetti, V., Gribaudo, G., Palu`, G., Pannecouque, C., Loregian, A., and Tabarrini, O. (2013). Design, synthesis, and evaluation of WC5 analogues as inhibitors of human cytomeg-alovirus Immediate-Early 2 protein, a promising target for anti-HCMV treat-ment. ChemMedChem. *8*, 1403–1414.

Mengoli, C., Cusinato, R., Biasolo, M.A., Cesaro, S., Parolin, C., and Palu`, G. (2004). Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection. J. Med. Virol. *74*, 78–84.

Mercorelli, B., Muratore, G., Sinigalia, E., Tabarrini, O., Biasolo, M.A., Cecchetti, V., Palu`, G., and Loregian, A. (2009). A 6-aminoquinolone com-pound, WC5, with potent and selective anti-human cytomegalovirus activity. Antimicrob. Agents Chemother. *53*, 312–315.

Mercorelli, B., Lembo, D., Palu`, G., and Loregian, A. (2011). Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives. Pharmacol. Ther. *131*, 309–329.

Mercorelli, B., Gribaudo, G., Palu`, G., and Loregian, A. (2014a). Approaches for the generation of new anti-cytomegalovirus agents: identification of protein-protein interaction inhibitors and compounds against the HCMV IE2 protein. Methods Mol. Biol. *1119*, 349–363.

Mercorelli, B., Luganini, A., Muratore, G., Massari, S., Terlizzi, M.E., Tabarrini, O., Gribaudo, G., Palu`, G., and Loregian, A. (2014b). The 6-aminoquinolone WC5 inhibits different functions of the immediate-early 2 (IE2) protein of human cytomegalovirus that are essential for viral replication. Antimicrob. Agents Chemother. *58*, 6615–6626.

Mocarski, E.S., Shenk, T., Griffiths, P.D., and Pass, R.F. (2013). Cytomegaloviruses. In Fields Virology, Sixth Edition, D.M. Knipe and P.M. Howley, eds. (Wolters Kluwer Lippincott Williams & Wilkins), pp. 1960–2014.

Moorman, N.J., and Shenk, T. (2010). Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J. Virol. *84*, 5260–5269.

Moretto, A., and Colosio, C. (2011). Biochemical and toxicological evidence of neurological effects of pesticides: the example of Parkinson's disease. Neurotoxicology *32*, 383–391.

Mousseau, G., Clementz, M.A., Bakeman, W.N., Nagarsheth, N., Cameron, M., Shi, J., Baran, P., Fromentin, R., Chomont, N., and Valente, S.T. (2012). An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. Cell Host Microbe *12*, 97–108.

Nogalski, M.T., Collins-McMillen, D., and Yurochko, A.D. (2014). Overview of human cytomegalovirus pathogenesis. Methods Mol. Biol. *1119*, 15–28.

Oh, S.H., Woo, J.K., Yazici, Y.D., Myers, J.N., Kim, W.Y., Jin, Q., Hong, S.S., Park, H.J., Suh, Y.G., Kim, K.W., et al. (2007). Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J. Natl. Cancer Inst. *99*, 949–961.

Revello, M.G., Lilleri, D., Zavattoni, M., Stronati, M., Bollani, L., Middeldorp, J.M., and Gerna, G. (2001). Human cytomegalovirus immediate-early messenger RNA in blood of pregnant women with primary infection and of congenitally infected newborns. J. Infect. Dis. *184*, 1078–1081.

Rossignol, J.F. (2014). Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral. Res. *110*, 94–103.

Rossignol, J.F., La Frazia, S., Chiappa, L., Ciucci, A., and Santoro, M.G. (2009). Thiazolides, a new class of anti-influenza molecules targeting viral hemagglu-tinin at the post-translational level. J. Biol. Chem. *284*, 29798–29808.

Sampaio, K.L., Cavignac, Y., Stierhof, Y.D., and Sinzger, C. (2005). Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. J. Virol. *79*, 2754–2767.

Scholz, M., Doerr, H.W., and Cinatl, J. (2001). Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? Antiviral. Res. *49*, 129–145.

Senkowski, W., Zhang, X., Olofsson, M.H., Isacson, R., Hoglund, U., Gustafsson, M., Nygren, P., Linder, S., Larsson, R., and Fryknas, M. (2015). Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer. Mol. Cancer Ther. *14*, 1504–1516.

Stachulski, A.V., Pidathala, C., Row, E.C., Sharma, R., Berry, N.G., Lawrenson, A.S., Moores, S.L., Iqbal, M., Bentley, J., Allman, S.A., et al. (2011). Thiazolides

as novel antiviral agents. 2. Inhibition of hepatitis C virus replication. J. Med. Chem. *54*, 8670–8680.

Stinski, M.F., and Petrik, D.T. (2008). Functional roles of the human cytomeg-alovirus essential IE86 protein. Curr. Top. Microbiol. Immunol. *325*, 133–152.

Taylor, R.T., and Bresnahan, W.A. (2005). Human cytomegalovirus immediate-early 2 gene expression blocks virus-induced beta interferon production. J. Virol. *79*, 3873–3877.

Taylor, R.T., and Bresnahan, W.A. (2006). Human cytomegalovirus IE86 atten-uates virus- and tumor necrosis factor alpha-induced NFkappaB-dependent gene expression. J. Virol. *80*, 10763–10771.

Waheed, I., Chiou, C.J., Ahn, J.H., and Hayward, G.S. (1998). Binding of the human cytomegalovirus 80-kDa immediate-early protein (IE2) to minor groove A/T-rich sequences bounded by CG dinucleotides is regulated by protein olig-omerization and phosphorylation. Virology *252*, 235–257.

Wang, Y., Ma, W., and Zheng, W. (2013). Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention. Mol. Clin. Oncol. *1*, 215–219.

Yan, C., and Higgins, P.J. (2013). Drugging the undruggable: transcription therapy for cancer. Biochim. Biophys. Acta *1835*, 76–85.

Zhang, J.H., Chung, T.D., and Oldenburg, K.R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening as-says. J. Biomol. Screen *4*, 67–73.

Supplemental Information

Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor

IE2 that Block Human Cytomegalovirus Replication

Beatrice Mercorelli, Anna Luganini, Giulio Nannetti, Oriana Tabarrini, Giorgio Palù, Giorgio Gribaudo, and Arianna Loregian

Supplemental Figure S1, Related to Figure 1 and Supplemental Experimental Procedures


Figure S1. Optimization of the Cell-Based Assay for the Screening.
U373 UL54-2F7 and UL112-113-1B4 cell lines were either mock-infected or infected with HCMV AD169 at different multiplicity of infection (MOI) and treated with 5 µM fomivirsen as a positive control or untreated. EGFP levels (expressed as Fluorescence Units [FU]) in cell-free supernatants were determined at 72 h p.i. after cell lysis. All data are represented as mean ± SD of three independent experiments; (*$p<0.01$ *versus* calibrator sample [HCMV-infected untreated U373 UL54-2F7 and UL112-113-1B4 cell lines]).

Supplemental Figure S2, Related to Figure 1 and Supplemental Experimental Procedures


Figure S2. Expression of Representative Viral IE, E, and L Proteins in HCMV-Infected U373 UL54-2F7 Cells.
U373 UL54-2F7 cells were either mock-infected or infected with HCMV AD169 (MOI 0.5 PFU/cell). At the indicated times p.i., whole-cell extracts were prepared and analyzed by Western Blot (WB) with antibodies specific for IE (IE1 and IE2), E (UL44), and L (UL55 and UL99) proteins. Tubulin immunodetection served as an internal control.

Figure S3. Effects of Addition of Hit Compounds and Fomivirsen on EGFP Expression at Different Time-Points after HCMV Infection of U373 UL54-2F7 Cells.

U373 UL54-2F7 cells were either mock-infected (N.I.) or infected with HCMV AD169 (MOI 0.5) and incubated with 10 μM hit compounds, or DMSO or 5 μM fomivirsen as controls, at the indicated times prior or after virus infection. EGFP levels (expressed as Fluorescence Units [FU]) in cell-free supernatants were determined at 72 h p.i. after cell lysis. All data are represented as mean ± SD of three independent experiments.

**Supplemental Figure S4, Related to Figure 5 and Supplemental Experimental Procedures**

Figure S4. Expression of the IE2 Protein in U373 UL54-2F7 Cells Transduced with AdVIE2. U373 UL54-2F7 cells were not transduced (mock) or transduced with AdVIE2 or AdVLacZ at MOI of 40 PFU/cell. At the indicated times p.i., whole-cell extracts were analyzed by WB with an anti-IE2 antibody. Tubulin immunodetection served as an internal control.

Figure S5. Intracellular Localization of IE2 in Infected, NTZ-treated HFF Cells.

The intracellular localization of IE2 in HFF cells infected with HCMV and treated with NTZ or DMSO as a control was analyzed by immunofluorescence with an anti-IE2 antibody at 8, 24, and 48 h p.i.. Nuclei were counterstained with TOTO-3 stain. Individual green (IE2) and blue (TOTO-3) channels and merged images are shown. Representative images of four independent experiments performed in duplicate are shown.

Supplemental Table S1. Table of the Hit Compounds Identified by Cell-based Screens, Related to Figure 1 and Experimental Procedures.

Compound	PubChem [a] CID	Bioactivity	Antiviral Activity EC$_{50}$ (µM)[b]	Cytotoxicity CC$_{50}$ (µM) [c]	[d] SI
Clotrimazole	2812	Antifungal	0.8 ± 0.6	40 ± 28	50
Hexachlorophene	3598	Antiinfective	0.3 ± 0.8	150 ± 68	500
Clioquinol	2788	Antiseptic, antiamebic	4.8 ± 3.6	42 ± 35	9
Edoxudine	66377	Antiviral	> 20	> 200	>10
Pararosaniline pamoate	11292	Antihelmintic, antischistosomal	5.5 ± 1.4	100 ± 36	18
Nitazoxanide	**41684**	**Antiparasitic**	**3.9 ± 1.6**	**>200**	**>51**
Nisoldipine	4499	Vasodilator (coronary)	3.8 ± 2.6	80 ± 21	21
Manidipine hydrochloride	4008	Antihypertensive	2.2 ± 2.8	>200	>91
Miconazole nitrate	68553	Antifungal	1.2 ± 0.6	55 ± 16	46
Azacitidine	9444	Antineoplastic, antimetabolite	> 20	> 200	>10
Papaverine hydrochloride	6084	Muscle relaxant, cerebral vasodilator	7.0 ± 2.9	>200	>29
Hydroxyprogesterone caproate	169870	Progestogen	> 20	> 200	>10
Cycloheximide	6197	Antipsoriatic, protein synthesis inhibitor	6.0 ± 1.3	>200	>33
Pentamidine isethionate	8813	Antiprotozoal	ND	< 20	ND
Oligomycin A	5281899	Antibacterial, antifungal	ND	< 20	ND
Econazole nitrate	68589	Antifungal	4.9 ± 2.3	85 ± 13	17
Nitroxoline	19910	Antibacterial	4.5 ± 2.4	100 ± 27	22
Salinomycin, sodium	53487842	Antibacterial	7.5 ± 1.0	50 ± 18	7
Dequalinium chloride	10649	Antiinfectant	ND	< 20	ND
Berberine chloride	12456	Antiarrhythmic, α2 agonist, anticonvulsant	1.3 ± 0.8	> 200	>160
Ethaverine hydrochloride	13796	Antispasmodic	5.0 ± 1.7	> 200	>50
Tioxolone	72139	Antiseborrhoic	> 20	> 200	>10
Alexidine dihydrochloride	**102678**	**Antibacterial**	**0.22 ± 0.2**	**15 ± 5**	**68**

Isorotenone	6453092	Natural substance	< 0.2	> 200	>1000
Antimycin A	3084471	Antifungal, antiviral	1.4 ± 0.9	> 200	>143
Pyrromycin	196990	Antibacterial	0.2 ± 0.6	30 ± 8	137
Mundulone acetate	4587968	Natural substance	> 20	> 200	>10
Ergosterol acetate	444679	Provitamin	> 20	> 200	>10
Deguelin(-)	**107935**	**Antineoplastic, antiviral, insecticide**	**0.6 ± 0.9**	**> 200**	**> 333**
Perseitol	441436	Natural substance	6.0 ± 1.5	>200	>33
Duartin(-)	3666064	Natural substance	0.9 ± 0.4	> 200	> 235
Mundoserone	3083809	Natural substance	6.1 ± 2.5	>200	>33
Rotenonic acid	4303568	Natural substance	> 20	> 200	>10
Thioguanosine	**2724387**	**Antineoplastic**	**0.7 ± 1.2**	**>200**	**>308**
2,4-dinitrophenol	1493	Uncouples oxidative phosphorylation	5.8 ± 1.7	100 ± 18	18
Apotoxicarol	ND	Natural substance	15.2 ± 8.6	> 200	> 13
Alpha-toxicarol	442826	Natural substance	3.2 ± 0.6	110 ± 27	31
Pentachlorophenol	992	Insecticide, herbicide	6.3 ± 1.1	75 ± 8	137

Supplemental Table S2. Table of the Antiviral Activity of Selected Hits Against a Panel of Different HCMV Strains, Related to Figure 2 and Experimental Procedures.

Antiviral Activity
EC_{50} $(\mu M)^a$

HCMV strain	Resistance	Control[b]	DGN	NTZ	TGN	AXN
TB40	None	2.7 ± 1.2	1.1 ± 0.5	3.1 ± 0.1	1.4 ± 0.9	0.16 ± 0.03
VR1814	None	6.6 ± 0.5	1.4 ± 0.9	3.5 ± 0.6	1.6 ± 1.7	0.23 ± 0.05
759[r]D100	GCV	54.2 ± 4.6	2.5 ± 1.9	3.7 ± 0.2	1.5 ± 0.2	0.80 ± 0.07
PFA[r]D100	FOS, ACV	200 ± 25	1.9 ± 0.1	3.0 ± 0.1	1.9 ± 0.1	0.20 ± 0.08

[a]EC_{50}, compound concentration that inhibits 50% of plaque formation, as determined by plaque reduction assays. Reported values represent the means $\pm$ the SD of data derived from three independent experiments in duplicate. [b]Ganciclovir (GCV) was used as a control in all plaque reduction assays, except for PFA[r]D100 strain, where foscarnet (FOS) was used as a control. ACV: acyclovir.

Supplemental Table S3. List of the Oligonucleotides Used in This Study, Related to Figure 3 and Experimental Procedures.

UL122 qPCR primer set	Primer FOR (CM-5T)	TCATCCACACTAGGAGAGCAGACT
	Primer REV (CM-3T)	GCCAAGCGGCCTCTGAT
	Probe	ACTGGGCAAAGACCTTCATGCAGATCTC
β-globin qPCR primer set	Primer FOR	AGGGCCTCACCACCAACTT
	Primer REV	GCACCTGACTCCTGAGGAGAA
	Probe	ATCCACGTTCACCTTGCCCCACA

Supplemental Table S4. List of the Primary Antibodies Used in This Study, Related to Figures 4, S4, and S5 and Experimental Procedures.

Antigen	Supplier	Clone ID	Usage
Tubulin	Sigma	TUB 2.1	WB (1:2,000)
IE1/IE2	Argene-Biosoft	E13	WB (1:400)
UL44	Virusys	CH16	WB (1:1,000)
UL55	Virusys	CH28	WB (1:1,000)
UL99	Virusys	CH19	WB (1:2,000)
IE2	Santa Cruz Biotech.	12E2	WB (1:1000); IF (1:100)

WB: Western Blot; IF: immunofluorescence.

Optimization of the Cell-Based Assay for the Screening, Related to Figure S1.

U373 UL54-2F7 and UL112-113-1B4 cells were seeded in 96-well plates at a density of 2×10^4/well and allowed to grow for 16 h. The next day, cells were pretreated for 2 h with 5 µM fomivirsen, and then infected with HCMV AD169 at different multiplicities of infection (MOI, from 0.1 to 10 PFU/cell). After a 2-h incubation at 37°C, viral inocula were removed and cells were incubated with 5 µM fomivirsen for 72 h at 37°C. Thereafter, cells were lysed in 0.1 ml of lysis buffer (50 mM Tris-HCl pH 7.8, 150 mM NaCl, 5 mM EDTA, 15 mM $MgCl_2$, 0.15% NP-40) for 30 min at 4°C and centrifuged. Finally, 90 µl of cell-free supernatants were transferred into 96-well black plates (Nunc) to quantify EGFP expression by fluorescence detection with Victor X2 (Perkin Elmer) after 5 min equilibration.

Analysis of HCMV Proteins Expression in U373 UL54-2F7 Cells by Western Blot, Related to Figure S2.

To verify the completion of the HCMV replication cycle in U373 cells, U373 UL54-2F7 cells were seeded in 6-well plates at a density of 3×10^5/well. The following day, cells were infected with HCMV AD169 at MOI of 0.5 PFU/cell for 2 h at 37°C. Whole-cell extracts were then prepared at 24, 48, and 72 h p.i. as described in the main text, fractionated by 8.5% SDS-PAGE, and then analyzed by WB with anti-IEA (IE1/IE2), anti-UL44, anti-UL55, anti-UL99, and anti-tubulin MAbs (Table S4).

Time-of-Addition Studies, Related to Figure S3.

For time-of-addition studies, U373 UL54-2F7 cells were seeded at a density of 2×10^4/well in 96-well plates and incubated overnight at 37°C. The next day, cells were infected with HCMV AD169 at MOI 0.5 PFU/cell for 2 h at 37°C. At the end, the viral inocula were removed and at different times (-2, 2, 4, 8, 24, 32, 48, 56 h p.i.) the cell medium was replaced with medium containing 10 µM of the hit compounds or 0.1% DMSO as a control. Cells were incubated at 37°C for a total of 72 h after infection; at this time point, cells were lysed and EGFP expression was determined as previously described.

Analysis of IE2 Protein Expression in AdVIE2 Transduced-U373 UL54-2F7 Cells by Western Blot, Related to Figure S4.

To verify the expression of the IE2 protein following transduction with AdVIE2, U373 UL54-2F7 were seeded at a density of 3×10^5/well in 6-well plates, and then transduced the following day with AdVIE2, or AdVLacZ, as a control, at an MOI of 40 PFU/cell. At different times post-infection, whole-cell extracts were prepared as described in the main text and analyzed by 8.5% SDS-PAGE and WB using anti-IE2 and anti-tubulin MAbs (Table S4).

Analysis of IE2 Nuclear Localization by Immunofluorescence, Related to Figure S5.

To analyze the intracellular localization of IE2, HFF cells at a density of 5×10^5/well seeded on coverslips were infected with HCMV AD169 (MOI 0.5) for 2 h at 37°C. At the end of the incubation, medium containing 30 µM NTZ, or DMSO as a control, was added and cells were incubated at 37°C. At 8, 24, and 48 h p.i., cells were fixed with 4% (v/v) formaldehyde in PBS for 20 min. After permeabilization with 0.3% Triton X-100 in PBS for 15 min at RT, cells were first incubated at RT for 1 h with 4% FBS in PBS, followed by incubation for 1 h at 37°C with an anti-IE2 Mab (Table S4). Following washes, an anti-mouse IgG FITC-conjugated antibody (Santa Cruz

Biotechnology) was added for 1 h at 37°C. Finally, cells were incubated for 20 min at RT with TOTO-3 iodide (Molecular Probes) and coverslips were mounted. Cells were imaged with a Leica TCS-NT/SP2 confocal microscope with a 40× objective and the images were digitally analyzed with Leica software.